The ITOR Clinical Research Unit (CRU) brings phase I cancer clinical trials to Greenville and surrounding Upstate, South Carolina areas. By providing access to this first stage of clinical pharmaceutical testing, the ITOR CRU makes it possible for patients to receive the most advanced cancer treatments available without the need to travel to distant locations.
ITOR Advances Cancer Care Through Clinical Trials
Cancer clinical trials help speed new drug development and ultimately provide more effective treatment options for patients. Through a demonstrated commitment to effectively testing cancer drugs, the ITOR CRU has established the reputation necessary to consistently draw early phase clinical trials to the area. The facility is staffed and equipped to conduct breakthrough cancer clinical trials utilizing the most advanced techniques and technologies.
The ITOR Clinical Research Unit averages 20 or more active trials at any given time. The unit specializes in molecular-driven solid tumor trials.
Since late 2004, the ITOR Clinical Research Unit has conducted more than 100 clinical trials. Our archived cancer trials have investigated live viral gene therapies, autologous tumor vaccines, and other early-phase therapies.
First in Human Trials
By conducting first in man trials, where drug testing is extended to human subjects for the first time, the ITOR Clinical Research Unit helps accelerate the development of safer, more effective drugs.
Biosafety Level ll Program
The ITOR Clinical Research Unit Biosafety Level II Program conducts gene transfer therapy trials. The ITOR CRU is the first unit in South Carolina to obtain Biosafety II accreditation for viral vector and gene transfer studies.
To learn more about participation in any of the active ITOR CRU cancer clinical trials, please review our patient enrollment information.